New supercomputer to simulate disease and search for drugs

NVIDIA has partnered with AstraZeneca and GlaxoSmithKline to develop a supercomputer for healthcare scientists to help diagnose and treat dementia, stroke, brain cancer, and multiple sclerosis earlier.

The Cambridge-1 supercomputer is designed for artificial intelligence (AI) research in healthcare.

The company plans to allocate Cambridge-1 resources in four areas: industry research, providing universities with computing power, medical AI startups, and education for future scientists in the field of AI.

Cambridge-1 will provide the world’s leading researchers with the ability to do their life’s work on the UK’s most powerful supercomputer, uncovering clues to diseases and treatments on a scale and speed never before possible in the UK.

Jen-Hsun Huang, Founder and CEO, Nvidia

According to the creators of the supercomputer, the new capabilities of artificial intelligence will help scientists better understand diseases such as:

  • dementia,
  • stroke,
  • brain cancer
  • multiple sclerosis.

The company said in a statement that it will work with its partners to share this knowledge with the wider scientific community.

The Cambridge-1 is ranked 41st among the world’s highest-performing supercomputers, according to the TOP500 ranking.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Author: John Kessler
Graduated From the Massachusetts Institute of Technology. Previously, worked in various little-known media. Currently is an expert, editor and developer of Free News.
Function: Director
John Kessler

Spelling error report

The following text will be sent to our editors:

30 number 0.226238 time